WallStSmart

Moderna Inc (MRNA)vsNutriband Inc (NTRB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 123499% more annual revenue ($2.23B vs $1.80M). NTRB leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09

NTRB

Avoid

13

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -6.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$134.97

Current Price

$143.97

$9.00 discount

UndervaluedFair: $134.97Overvalued

Intrinsic value data unavailable for NTRB.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

NTRB1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Areas to Watch

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

NTRB4 concerns · Avg: 3.5/10
Price/BookValuation
14.2x4/10

Trading at 14.2x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$72.57M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bull Case : NTRB

The strongest argument for NTRB centers on Debt/Equity.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Bear Case : NTRB

The primary concerns for NTRB are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

MRNA profiles as a turnaround stock while NTRB is a value play — different risk/reward profiles.

NTRB carries more volatility with a beta of 2.04 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

NTRB generates stronger free cash flow (-585,003), providing more financial flexibility.

Bottom Line

MRNA scores higher overall (21/100 vs 13/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Nutriband Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Nutriband Inc. develops a portfolio of transdermal pharmaceuticals. The company is headquartered in Orlando, Florida.

Want to dig deeper into these stocks?